S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients

Autor: Lukas B. Been, Robert J. van Ginkel, Schelto Kruijff, Kevin Wevers, Barbara L. van Leeuwen, Harald J. Hoekstra, Anneke C. Muller Kobold, Samantha Damude, Otis M. Vrielink, Eric A. Deckers
Přispěvatelé: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Clinical Cognitive Neuropsychiatry Research Program (CCNP)
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
PROTEIN
Metastasis
0302 clinical medicine
Positron Emission Tomography Computed Tomography
follow-up
Lymph node
Research Articles
Aged
80 and over
medicine.diagnostic_test
Melanoma
General Medicine
Middle Aged
DABRAFENIB
Dissection
medicine.anatomical_structure
Oncology
Positron emission tomography
030220 oncology & carcinogenesis
S‐100B
biomarker
030211 gastroenterology & hepatology
Female
Radiology
medicine.symptom
medicine.drug
Research Article
CT
Adult
medicine.medical_specialty
recurrence
Physical examination
S100 Calcium Binding Protein beta Subunit
Asymptomatic
POOLED ANALYSIS
03 medical and health sciences
Fluorodeoxyglucose F18
medicine
Biomarkers
Tumor
melanoma
Humans
Aged
Neoplasm Staging
Fluorodeoxyglucose
follow‐up
business.industry
medicine.disease
FDG PET/CT
FDG PET
Surgery
Neoplasm Recurrence
Local
Radiopharmaceuticals
business
S-100B
Follow-Up Studies
Zdroj: Journal of Surgical Oncology, 120(6), 1031-1037. Wiley
Journal of Surgical Oncology
ISSN: 0022-4790
Popis: Background and Objectives This current study assessed the value of S‐100B measurement to guide fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning for detecting recurrent disease in stage III melanoma patients. Methods This study included 100 stage III melanoma patients in follow‐up after curative lymph node dissection. Follow‐up visits included physical examination and S‐100B monitoring. FDG PET/CT scanning was indicated by clinical symptoms and/or elevated S‐100B. Results Of 100 patients, 13 (13%) had elevated S‐100B without clinical symptoms, of whom 7 (54%) showed disease evidence upon FDG PET/CT scanning. Twenty‐six patients (26%) had clinical symptoms with normal S‐100B and FDG PET/CT revealed metastasis in 20 (77%). Three patients had clinical symptoms and elevated S‐100B, and FDG PET/CT revealed metastasis in all three (100%). Overall, FDG PET/CT scanning revealed metastasis in 30 of the 42 patients (71.4%). For seven recurrences, elevated S‐100B prompted early detection of asymptomatic disease; 10% of all asymptomatic patients in follow‐up, 23% of all patients with recurrent disease. Conclusion S‐100B cannot exclude recurrent disease during follow‐up of stage III melanoma. However, adding S‐100B measurement to standard clinical assessment can guide FDG PET/CT scanning for detecting recurrent melanoma.
Databáze: OpenAIRE
Externí odkaz: